Union Therapeutics starts phase II trial of nasal spray for Covid-19 patients

Biotech company Union Therapeutics is testing its candidate niclosamide as a nasal spray for patients infected with Covid-19 who are either asymptomatic or mildly symptomatic in a phase II study.
Photo: Union Therapeutics / PR
Photo: Union Therapeutics / PR

The Danish biotech company Union Therapeutics has enrolled the first patient in its phase II trial of drug candidate niclosamide as a treatment for Covid-19 patients, it reports in a press release.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading